In recent years, immune checkpoint inhibitor (ICI) therapy, particularly applying antibodies targeting the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway, has been a significant component of numerous combination regimens in advanced HCC (11–13). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.